ABSTRACT
Although lifespan extension remains the gold standard for assessing interventions hypothesized to impact the biology of aging, there are important limitations to this approach. Our reanalysis of lifespan studies from multiple sources suggests that the use of short-lived control cohorts tends to exaggerate the relative efficacy of putative longevity interventions. Moreover, due to the high cost and long timeframes of mouse studies, it is rare that a particular longevity intervention will be independently replicated by multiple groups.
To facilitate identification of successful interventions, we propose an alternative approach. The level of confidence we can have in an intervention is proportional to the degree of lifespan extension above the strain- and species-specific upper limit of lifespan, which we can estimate from comparison to historical controls. In the absence of independent replication, a putative mouse longevity intervention should only be considered with high confidence when control lifespans are close to 900 days or if the final lifespan of the treated group is considerably above 900 days. Using this “900-day rule” we identified several candidate interventions from the literature that merit follow-up studies.
Competing Interest Statement
The authors have declared no competing interest.
Abbreviations
- ITP
- Interventions Testing Program
- CR
- caloric restriction
- ILSXISS
- recombinant inbred cross of ILS (Inbred Long Sleep, ILS) and ISS (Inbred Short Sleep, ISS) mice
- FGF-21
- fibroblast growth factor 21
- GH
- growth hormone